貴州百靈(002424.SZ):簽訂技術開發(合作)合同 涉及醫療機構製劑“糖寧通絡片”項目的研究和開發
格隆匯5月25日丨貴州百靈(002424.SZ)公佈,公司於2021年5月25日與山東第一醫科大學附屬省立醫院(“甲方”)簽訂《技術開發(合作)合同》。
雙方擬共同參與醫療機構製劑“糖寧通絡片”項目的研究和開發,本着風險共擔,利益雙贏的原則,雙方經過平等協商,在真實、充分地表達各自意願的基礎上,根據《中華人民共和國民法典》的規定,達成合同,並由雙方共同恪守。
“糖寧通絡”是公司基於貴州苗藥開發的醫療機構製劑,已按《醫療機構製劑註冊管理辦法》(試行)(局令第20號)的要求,完成臨牀前研究工作,具有良好的成藥性,已經獲得貴州省、湖南省、內蒙古自治區、廣西壯族自治區《醫療機構製劑注冊批件》,正在中國人民解放軍總醫院、廣東省中醫院、中國中醫科學院廣安門醫院、雲南省中醫醫院申報醫療機構製劑,目前已在貴州省內調劑至包括6家三甲醫院在內的20多家醫院使用。經過臨牀實踐和觀察證實,“糖寧通絡”對II型糖尿病患者具有良好的療效。
此次公司與山東第一醫科大學附屬省立醫院簽訂合同,將進一步擴大“糖寧通絡”適用的醫療機構範圍,有利於“糖寧通絡”在山東的宣傳、學術、推廣工作,為公司增加新的利潤增長點,提高公司的競爭力和持續盈利能力,對公司的戰略佈局起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.